Patents by Inventor Shaun R. Opie

Shaun R. Opie has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS OF GENE DELIVERY USING CAPSID-MODIFIED RAAV EXPRESSION SYSTEMS
    Publication number: 20150005369
    Abstract: Disclosed are methods of gene delivery using capsid-modified recombinant adeno-associated viral (rAAV) vectors. Exemplary methods are provided employing vectors that have altered affinity for heparin or heparin sulfate, as well as vectors, expression systems, and rAAV virions that lack functional VP2 protein expression, but are nevertheless, fully virulent. Also provided by the invention are methods employing the rAAV vector-based compositions, virus particles, host cells, and pharmaceutical formulations in the expression of selected therapeutic proteins, polypeptides, peptides, antisense oligonucleotides and/or ribozymes in selected mammals, including organs, tissues, and human host cells.
    Type: Application
    Filed: July 8, 2014
    Publication date: January 1, 2015
    Inventors: Nicholas Muzyczka, Shaun R. Opie, Kenneth H. Warrington
  • Raav expression systems for genetic modification of specific capsid proteins
    Patent number: 8802080
    Abstract: Disclosed are improved recombinant adeno-associated viral (rAAV) vectors having mutations in one or more capsid proteins. Exemplary vectors are provided that have altered affinity for heparin or heparin sulfate, as well as vectors, expression systems, and rAAV virions that lack functional VP2 protein expression, but are nevertheless, fully virulent. Also provided by the invention are rAAV vector-based compositions, virus particles, host cells, and pharmaceutical formulations that comprise them useful in the expression of selected therapeutic proteins, polypeptides, peptides, antisense oligonucleotides and/or ribozymes in selected mammals, including organs, tissues, and human host cells.
    Type: Grant
    Filed: May 1, 2003
    Date of Patent: August 12, 2014
    Assignee: University of Florida Research Foundation, Inc.
    Inventors: Kenneth H. Warrington, Shaun R. Opie, Nicholas Muzyczka
  • METHODS FOR TARGETING MODIFIED RAAV VECTORS TO MAMMALIAN CELLS
    Publication number: 20090286321
    Abstract: Disclosed are improved VP2-modified recombinant adeno-associated viral (rAAV) vectors, expression systems, and rAAV virions that are fully virulent, yet lack functional VP2 protein expression. Also disclosed are pharmaceutical compositions, virus particles, host cells, and pharmaceutical formulations that comprise these modified vectors useful in the expression of therapeutic proteins, polypeptides, peptides, antisense oligonucleotides and/or ribozymes in the cells and tissues of selected mammals, including, for example, human tissues and host cells.
    Type: Application
    Filed: January 30, 2009
    Publication date: November 19, 2009
    Applicant: The University of Florida Research Foundation, Inc.
    Inventors: Kenneth H. Warrington, Shaun R. Opie, Nicholas Muzyczka
  • rAAV EXPRESSION SYSTEMS AND COMPOSITIONS
    Publication number: 20090149414
    Abstract: Disclosed are improved VP2-modified recombinant adeno-associated viral (rAAV) vectors, expression systems, and rAAV virions that are fully virulent, yet lack functional VP2 protein expression. Also disclosed are pharmaceutical compositions, virus particles, host cells, and pharmaceutical formulations that comprise these modified vectors useful in the expression of therapeutic proteins, polypeptides, peptides, antisense oligonucleotides and/or ribozymes in the cells and tissues of selected mammals, including, for example, human tissues and host cells.
    Type: Application
    Filed: January 30, 2009
    Publication date: June 11, 2009
    Applicant: THE UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC.
    Inventors: KENNETH H. WARRINGTON, SHAUN R. OPIE, NICHOLAS MUZYCZKA
  • VIRAL VECTOR-BASED GENE THERAPY METHODS AND COMPOSITIONS
    Publication number: 20090148411
    Abstract: Disclosed are improved VP2-modified recombinant adeno-associated viral (rAAV) vectors, expression systems, and rAAV virions that are fully virulent, yet lack functional VP2 protein expression. Also disclosed are pharmaceutical compositions, virus particles, host cells, and pharmaceutical formulations that comprise these modified vectors useful in the expression of therapeutic proteins, polypeptides, peptides, antisense oligonucleotides and/or ribozymes in the cells and tissues of selected mammals, including, for example, human tissues and host cells.
    Type: Application
    Filed: January 30, 2009
    Publication date: June 11, 2009
    Applicant: The University of Florida Research Foundation, Inc
    Inventors: Kenneth H. Warrington, Shaun R. Opie, Nicholas Muzyczka
  • rAAV Expression Systems and Methods of Use
    Publication number: 20090148949
    Abstract: Disclosed are improved VP2-modified recombinant adeno-associated viral (rAAV) vectors, expression systems, and rAAV virions that are fully virulent, yet lack functional VP2 protein expression. Also disclosed are pharmaceutical compositions, virus particles, host cells, and pharmaceutical formulations that comprise these modified vectors useful in the expression of therapeutic proteins, polypeptides, peptides, antisense oligonucleotides and/or ribozymes in the cells and tissues of selected mammals, including, for example, human tissues and host cells.
    Type: Application
    Filed: January 30, 2009
    Publication date: June 11, 2009
    Applicant: THE UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC
    Inventors: KENNETH H. WARRINGTON, SHAUN R. OPIE, NICHOLAS MUZYCZKA